On January 11, 2021 Alligator Bioscience AB (publ)’s ("Alligator" or the "Company") reported that rights issue of shares which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization from the Annual General Meeting on May 5, 2020 (the "Rights Issue") (Press release, Alligator Bioscience, JAN 11, 2021, View Source [SID1234573769]). The general public also has the opportunity to subscribe for shares in the Rights Issue.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
To ensure continued successful development in accordance with the Company’s business plan and strategy, the Board of Directors of Alligator has resolved to carry out the Rights Issue of approximately SEK 86 million before issue costs. The expected net proceeds from the Rights Issue will be used to initiate and conduct Phase II studies for mitazalimab and to complete phase I study and initiate preparatory work on Phase II study for ATOR-1017. The Rights Issue is secured to 100 per cent by subscription undertakings and guarantee commitments.
For complete information on the Rights Issue, please see the prospectus (the "Prospectus"), which has been prepared by the Board of Directors in connection with the Rights Issue.
Comment from Alligator’s CEO, Per Norlén
"With the capital injection from the rights issue, we secure the start of important efficacy studies for our focus projects mitazalimab and ATOR-1017. Just before year-end, we submitted a CTA for mitazalimab, an application to start Phase II in pancreatic cancer. For ATOR-1017, we plan to start Phase II studies in the second half of 2021, with gastric cancer as a prioritized indication. Based on strong data from preclinical models and clinical Phase I, we see great opportunities for both mitazalimab and ATOR-1017 to successfully treat patients with these cancers."– Per Norlén, CEO of Alligator
The Rights Issue
The Rights Issue comprises a maximum of 14,277,723 shares. The Rights Issue takes place with priority for those who were registered as shareholders in the Company on the record date, January 5, 2021. One (1) existing share in the Company entitles to one (1) subscription right. Five (5) subscription rights entitle to subscribe for one (1) new share.
Timeline for the Rights Issue
January 11 – January 21, 2021 – Trading in subscription rights
January 11 – January 25, 2021 – Subscription period
January 11, 2021 – Until the Rights Issue has been registered by the Swedish Companies Registration Office – Trading in paid-up subscribed shares (Sw. "BTA")
January 28, 2021 – Estimated publication of outcome of Rights Issue
Investor presentations
The Company will be presenting at Redeye Fight Cancer Seminar on January 21, 2021. Additional investor presentations may be arranged during the subscription period. Invitations will be presented on Alligator’s and Redeye AB’s respective websites.
Prospectus
The Prospectus, containing complete terms and conditions, is available on the Company’s, Aktieinvest FK AB’s and Redeye AB’s respective websites (www.alligatorbioscience.com, View Source and View Source). The Prospectus is also available on the Swedish Financial Supervisory Authority’s website (www.fi.se). Subscription forms are available on the Company’s and Redeye AB’s respective websites. Subscription forms can also be obtained by contacting Aktieinvest FK AB on telephone number 08-5065 1795.
Advisers
Redeye AB acts as financial adviser, Setterwalls Advokatbyrå AB acts as legal adviser and Aktieinvest FK AB acts as issuing agent in connection with the Rights Issue.